Research programme: antiviral agents - Schering-Plough/NeoGenesis

Drug Profile

Research programme: antiviral agents - Schering-Plough/NeoGenesis

Alternative Names: Antivirals research programme - Schering-Plough/NeoGenesis

Latest Information Update: 22 Apr 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeoGenesis; Schering-Plough
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Viral infections

Most Recent Events

  • 10 Aug 2001 Preclinical development for Viral infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top